导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.78% | 2015/4773 |
| 近一周 | -2.82% | 3195/5462 |
| 近一月 | -0.55% | 789/5421 |
| 近一季 | -0.50% | 843/5209 |
| 近半年 | -6.15% | 3024/4920 |
| 近一年 | -1.04% | 2821/4366 |
| 近两年 | 37.02% | 2010/2954 |
| 近三年 | 30.92% | 1017/2253 |
| 成立以来 | 32.43% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.75% 667/4961 |
-11.57% 4309/5312 |
- - |
- - |
| 2025 | 15.70% 2518/4813 |
0.68% 1790/3635 |
8.64% 323/4076 |
5.66% 3572/4524 |
0.11% 2215/4813 |
| 2024 | 18.46% 601/3463 |
2.60% 747/2808 |
9.36% 51/3014 |
5.54% 2877/3129 |
0.04% 1281/3463 |
| 2023 | -2.37% 577/2656 |
3.78% 1127/2280 |
-0.99% 433/2385 |
-2.21% 638/2515 |
-2.83% 542/2655 |
| 2022 | -9.18% 168/2207 |
-2.24% 149/1919 |
-0.61% 1640/2016 |
-12.23% 677/2113 |
6.51% 361/2208 |
| 2021 | 1.96% 644/1822 |
7.27% 77/1255 |
0.93% 1074/1330 |
-1.61% 534/1466 |
-4.28% 1477/1822 |
| 2020 | -2.45% 957/1250 |
-14.48% 962/1028 |
3.95% 921/1067 |
3.91% 963/1164 |
5.59% 779/1184 |
| 2019 | 13.44% 706/1092 |
14.66% 694/754 |
-4.66% 435/804 |
-6.21% 808/850 |
10.65% 109/918 |
| 2018 | - - |
- - |
- - |
- - |
-5.52% 35/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 银河中证沪港深高股息A VS. 长安沪深300非周期A(740101) |